Skip to main content
. 2022 Jan 11;7(1):e153165. doi: 10.1172/jci.insight.153165

Table 2. Sangivamycin is more efficacious than remdesivir against SARS-CoV-2 variants.

graphic file with name jciinsight-7-153165-g026.jpg